Clinical Trials Browser

Phase 2 × Immunoglobulins, Intravenous × 90 days × Clear all

NCT04438382 2026-06-02

Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients With Steroid-Refractory Pneumonitis

Phase 2 Terminated

1 enrolled 1 chart

Other hematologic neoplasm

Hematologic Neoplasms